Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
NCT05569512 · Malika Kapadia · PHASE1 · terminated · last registry update 2024-08-19 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for NCT05569512 following company restructuring. This notification came ahead of the study meeting criteria to progress from Phase 1 to Phase 2.” | Open Targets' class: business administrative | Registry record, Malika Kapadia |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SELE in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision